$10.28 Million in Sales Expected for Affimed (NASDAQ:AFMD) This Quarter

Wall Street analysts predict that Affimed (NASDAQ:AFMD) will report $10.28 million in sales for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Affimed’s earnings, with the highest sales estimate coming in at $13.14 million and the lowest estimate coming in at $5.76 million. Affimed posted sales of $11.62 million during the same quarter last year, which would indicate a negative year over year growth rate of 11.5%. The business is expected to announce its next quarterly earnings results on Thursday, April 21st.

On average, analysts expect that Affimed will report full-year sales of $45.15 million for the current fiscal year, with estimates ranging from $40.32 million to $49.66 million. For the next fiscal year, analysts expect that the firm will report sales of $69.54 million, with estimates ranging from $16.89 million to $199.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that follow Affimed.

Affimed (NASDAQ:AFMD) last issued its quarterly earnings results on Wednesday, November 10th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.01). Affimed had a negative return on equity of 40.23% and a negative net margin of 132.18%. During the same period in the previous year, the company posted ($0.08) EPS.

AFMD has been the subject of a number of research analyst reports. Truist Securities initiated coverage on Affimed in a research report on Thursday, October 21st. They issued a “buy” rating and a $10.00 target price for the company. Berenberg Bank initiated coverage on Affimed in a research report on Wednesday, November 17th. They issued a “buy” rating for the company. Zacks Investment Research raised Affimed from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 14th. SVB Leerink reaffirmed a “buy” rating and set a $12.00 price objective on shares of Affimed in a research report on Sunday, November 14th. Finally, Truist began coverage on Affimed in a research report on Thursday, October 21st. They set a “buy” rating and a $10.00 price objective for the company. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Affimed has an average rating of “Buy” and a consensus target price of $12.13.

Shares of NASDAQ AFMD traded up $0.26 during trading hours on Monday, reaching $7.07. The stock had a trading volume of 2,607,580 shares, compared to its average volume of 2,052,802. The firm has a market cap of $694.89 million, a price-to-earnings ratio of -12.85 and a beta of 2.58. The company has a current ratio of 3.07, a quick ratio of 3.06 and a debt-to-equity ratio of 0.08. Affimed has a fifty-two week low of $4.78 and a fifty-two week high of $11.74. The firm has a 50-day moving average of $6.28 and a 200-day moving average of $7.05.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AFMD. Meeder Asset Management Inc. purchased a new position in Affimed in the 2nd quarter valued at approximately $71,000. HighTower Advisors LLC purchased a new position in Affimed in the 2nd quarter valued at approximately $85,000. Schonfeld Strategic Advisors LLC purchased a new position in Affimed in the 2nd quarter valued at approximately $88,000. Boothbay Fund Management LLC purchased a new position in Affimed during the second quarter worth $90,000. Finally, Lindbrook Capital LLC increased its position in Affimed by 30.0% during the second quarter. Lindbrook Capital LLC now owns 11,700 shares of the biopharmaceutical company’s stock worth $99,000 after buying an additional 2,700 shares in the last quarter. 73.02% of the stock is owned by hedge funds and other institutional investors.

Affimed Company Profile

Affimed NV engages in the discovery and development of cancer immunotherapies. It offers ROCK novel proprietary antibody platform, which delivers types of next-generation tetravalent antibody formats, including bispecific and trispecific innate cell engagers. It operates through the following geographical segments: Germany, Europe, and USA.

Recommended Story: What is a price target?

Get a free copy of the Zacks research report on Affimed (AFMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.